期刊文献+

The optimal choice of chemotherapy regimens for patients with relapsed platinum-resistant epithelial ovarian cancer/primary peritoneal/fallopian tube cancer - protocol for a systematic review and network meta-analysis

The optimal choice of chemotherapy regimens for patients with relapsed platinum-resistant epithelial ovarian cancer/primary peritoneal/fallopian tube cancer - protocol for a systematic review and network meta-analysis
下载PDF
导出
摘要 Objective: Debulking surgery (residual disease of less than 1 cm) followed by platinum-taxane chemotherapy isthe current standard therapy for patients with epithelial ovarian cancer, primary peritoneal carcinoma and primaryfallopian cancer. But the prognosis remains poor. Several chemotherapy regimens could be selected for patientswith recrudescent cancer. However, the standard second chemotherapy regimen remains a subject of debate. Thepurpose of our study is to carry out a systematic review and network meta-analysis to compare the efficacy andsafety of different regimens for recurrent platinum-resistant ovarian cancer based on existing randomized controlledtrials (RCTs). Methods and analysis: Medline, EMBASE, Cochrane Library and Cochrane Library databases,Science Citation Index Expanded, Conference Proceedings Citation Index-Science and ClinicalTrials.gov will besystematically searched for eligible studies. Randomized controlled trials (RCT) on chemotherapy, immune therapy,biological therapy, targeted therapy for recurrent platinum-resistant ovarian cancer with multiple outcome measureswill be included. The Cochrane Risk of Bias Tool will be used to assess the quality of included studies. The primaryoutcomes are overall survival and median survival time. The secondary outcomes include the safety and side effectsof these regimens. Direct meta-analysis and network meta-analysis (NMA) will be conducted to compare differentregimens. Conclusion: The results of this network meta-analysis will provide direct and indirect evidence oftreatments for recurrent platinum-resistant ovarian cancer, and it may provide a ranking of the chemotherapyregimens for patients and gynecological oncologists to help them select the best option. 目的:上皮性卵巢癌、原发性腹膜癌、输卵管癌预后较差,减瘤术联合紫杉醇加铂类化疗是目前的首选方案.由于其二线化疗方案的选择较多,目前并无标准首选方案,本计划书将对应用网状meta分析对铂类耐药的卵巢癌二线化疗方案的优化选择进行先期计划.方法:选取Medline, EMBASE, Cochrane Library and Cochrane Library databases, Science Citation Index Expanded, Conference Proceedings Citation Index-Science, ClinicalTrials.gov数据库进行文献检索.纳入复发耐药型卵巢癌化疗,免疫治疗,生物治疗,靶向治疗的随机对照试验.应用CochraneRiskofBiasTool评估纳入的文献质量.主要观察指标为:中位生存期和整体生存率.次要观察指标为:有效性和安全性方面的评价.应用直接meta分析与间接meta分析(应用networkmeta-analysis(NMA))进行数据统计.结论:应用networkmeta分析,对复发性铂类耐药的随机对照试验提供的数据进行直接和间接比较,将可能对试验涉及的多种治疗方案的效果和安全性进行优化排序,为临床医师在实际工作中提供建议.
出处 《TMR Integrative Medicine》 2017年第1期30-36,共7页 TMR整合医学
关键词 Epithelial ovarian cancer CHEMOTHERAPY Network meta-analysis PROTOCOL 上皮性卵巢癌,化疗,网状meta分析,科学实验计划
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部